Activity of doripenem against extended-spectrum β-lactamase-producing Enterobacteriaceae and isolates

C. Betriu (1) , M. Gómez (1) , F. López-Fabal (1) , E. Culebras (1) , I. Rodríguez-Avial (1) , J. J. Picazo (1)

1 Servicio de Microbiología Clínica

The in vitro activity of doripenem was evaluated against a recent collection of extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae and isolates (201 ESBL-producing Enterobacteriaceae [153 and 48 ] and 201 ). Comparator agents included amikacin, tobramycin, ciprofloxacin, cefepime, cefotaxime, ceftazidime piperacillin-tazobactam, imipenem, and meropenem. Both doripenem and meropenem inhibited 100% of the ESBL-producing Enterobacteriaceae at ≤0.5 µg/mL. For these isolates, the MIC of doripenem (0.12 µg/mL) was 4-fold lower than that of imipenem (0.5 µg/mL). Against , the MIC of doripenem and meropenem was 2 µg/mL, 4-fold lower than that of imipenem (8 µg/mL). At an MIC of ≤2 µg/mL, doripenem, meropenem, and imipenem inhibited 90.5%, 89.6%, and 82.1% of isolates, respectively. Doripenem maintained activity against imipenem-nonsusceptible isolates of ; at an MIC of ≤4 µg/mL, it inhibited 15 of the 25 isolates with MICs for imipenem of >4 µg/mL. Doripenem is active against ESBL-producing Enterobacteriaceae and isolates. Its activity is similar to that of meropenem and slightly better than that of imipenem. The results of this study suggest that doripenem could be an alternative therapeutic agent for infections caused by these organisms.

Mots clés: Life Sciences

C. Betriu, M. Gómez, F. López-Fabal, E. Culebras, I. Rodríguez-Avial, et al.. Activity of doripenem against extended-spectrum β-lactamase-producing Enterobacteriaceae and isolates. European Journal of Clinical Microbiology and Infectious Diseases, 2010, 29 (9), pp.1179-1181. ⟨10.1007/s10096-010-0974-3⟩. ⟨hal-00598098⟩